Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000760025 | SCV000544213 | uncertain significance | not provided | 2024-12-28 | criteria provided, single submitter | clinical testing | This sequence change replaces alanine, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 1885 of the POLE protein (p.Ala1885Thr). This variant is present in population databases (rs748008084, gnomAD 0.009%). This missense change has been observed in individual(s) with breast cancer (PMID: 33558524). ClinVar contains an entry for this variant (Variation ID: 405886). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt POLE protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Quest Diagnostics Nichols Institute San Juan Capistrano | RCV000760025 | SCV000889772 | uncertain significance | not provided | 2017-10-09 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000760025 | SCV001825408 | uncertain significance | not provided | 2023-03-07 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant does not alter protein structure/function; Observed in an individual with breast cancer (Moradian et al., 2021); This variant is associated with the following publications: (PMID: 31034466, 33558524) |
Genetics and Molecular Pathology, |
RCV000471957 | SCV002556505 | uncertain significance | Colorectal cancer, susceptibility to, 12 | 2020-06-05 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004943870 | SCV005481526 | uncertain significance | Hereditary cancer-predisposing syndrome | 2024-10-17 | criteria provided, single submitter | clinical testing | The p.A1885T variant (also known as c.5653G>A), located in coding exon 41 of the POLE gene, results from a G to A substitution at nucleotide position 5653. The alanine at codon 1885 is replaced by threonine, an amino acid with similar properties. This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Based on the available evidence, the clinical significance of this variant remains unclear. |
Center of Medical Genetics and Primary Health Care | RCV001269354 | SCV001448692 | uncertain significance | Malignant tumor of breast | no assertion criteria provided | clinical testing |